Stereotaxis Targets $40M+ Revenue as MAGiC Ramps ($STXS)

Stereotaxis (STXS) management used the Q1 2026 earnings call to set a concrete revenue target: annual revenue is expected to surpass $40 million, with the third and fourth quarters each exceeding $10 million. The guidance ties directly to the commercial ramp of the MAGiC catheter and the Synchrony robotic system, two product lines that have now cleared key regulatory hurdles.

The $40 million-plus outlook implies a steep acceleration from current run-rates. Management explicitly called for Q3 and Q4 above $10 million apiece, meaning the first half of 2026 will carry a lighter revenue load while catheter supply scales. That back-half weighting is not unusual for a medtech launch. It concentrates execution risk into a narrow window. If the MAGiC ramp hits any supply or adoption snags, the full-year number becomes difficult to reach because the second-half quarters carry the bulk of the target.

The revenue bridge rests on two drivers. First, the Synchrony system, Stereotaxis’s next-generation robotic magnetic navigation platform, is now in commercial deployment. Second, the MAGiC catheter – a magnetically guided ablation catheter – is moving from regulatory clearance to volume production. The combination gives Stereotaxis a proprietary closed-loop offering in robotic electrophysiology, a segment where capital equipment sales and disposable catheter pull-through are tightly linked.

MAGiC FDA Clearances and Catheter Supply Ramp

The call highlighted multiple FDA clearances for the MAGiC catheter, removing the last major regulatory gate before a full commercial push. With clearances in hand, Stereotaxis is now focused on scaling catheter manufacturing to meet expected demand. Management described the supply ramp as the primary operational priority for the next two quarters.

A catheter supply ramp in a robotic-ablation system is not a simple volume play. Each MAGiC catheter must integrate with the Synchrony magnetic navigation field, and production yields, sterilization throughput, and distribution logistics all affect how quickly units reach electrophysiology labs. The guidance implies that Stereotaxis believes it can produce enough catheters to support $10 million-plus quarterly revenue by the second half. Any delay in that ramp would directly compress the back-half numbers.

J&J Transition: The Overhang on Execution

A significant variable discussed on the call is the transition away from Johnson & Johnson’s Biosense Webster as the primary catheter partner. Stereotaxis previously relied on J&J for manufacturing and commercial distribution of its ablation catheters. The move to direct control – or to a new manufacturing arrangement – introduces execution risk that management acknowledged.

Transition risks typically include production line qualification, inventory build, and the handoff of customer relationships. For Stereotaxis, the timing matters because the MAGiC launch is happening concurrently with this supply-chain shift. If the transition creates even a temporary catheter shortage, the back-half revenue weighting could slip. The call did not provide a specific completion date for the transition, leaving it as an open variable that the market will need to track through quarterly updates.

Q2 2026 Report: The First Real Test

The Q2 2026 report becomes the first real test of the ramp. Investors will look for MAGiC catheter shipment volumes, any update on the J&J transition timeline, and whether Stereotaxis reaffirms the $40 million-plus target. A sequential revenue step-up from Q1 to Q2 would provide early confirmation that the supply chain is functioning. Without that, the back-half weighting becomes a bet on a compressed timeline rather than a visible trajectory.

For traders tracking the name, the setup is straightforward: the guidance provides a clear yardstick, and the next print either validates the ramp or forces a re-rating of execution risk. The stock market analysis framework for medtech launches often rewards early revenue inflection. It punishes supply-driven misses sharply. The best stock brokers covering small-cap medtech will likely adjust price targets based on Q2 catheter unit data rather than the full-year headline.